Document is current
Any future updates will be listed below
-
Authors
Rosenfeld, William E. https://orcid.org/0000-0002-9504-3980
Klein, Pavel https://orcid.org/0000-0001-7244-3722
Ferrari, Louis https://orcid.org/0009-0006-1079-0677
Villanueva, Vicente https://orcid.org/0000-0003-2080-8042
-
Funding
Funding for this research was provided by:
SK Life Science
- License Information
-
More Information
Article History
Received: 4 June 2026
Accepted: 4 August 2026
First Online: 31 August 2026
Declarations
Conflict of Interest: William E. Rosenfeld: Consultant/advisor: SK Life Science, Inc.; Speaker: SK Life Science, Inc.; Research support: SK Life Science, Inc., UCB Pharma. Pavel Klein: Consultant/advisor and/or speaker: Abbott, Angelini, Aquestive, Arvelle, Aucta, Biogen, Dr Reddy’s, Eisai, Engage, Greenwich, GRIN Therapeutics, Jazz, Longboard, Lundbeck, Neurelis, Neurona, Paladin, SK Life Science, Inc., Stratus, Sunovion, UCB Pharma, UNEEG Medical, uniQure, Xenon; Research support: Citizens United for Research in Epilepsy (CURE), National Institute of Neurological Disorders and Stroke (NINDS); Scientific Advisory Board for NEUmiRNA, OB Pharma; CEO, PrevEp, LLC. Louis Ferrari: Employee, SK Life Science, at the time the manuscript was written. Vicente Villanueva: Consultant/advisor: Angelini, BIAL, Biocodex, Eisai, Esteve, Exeltis, Jazz, Novartis, Rapport, Takeda, UCB Pharma, Xenon; Speaker: Adium, Angelini, BIAL, Eisai, Esteve, Jazz, Paladin, UCB Pharma; Research support: Angelini, BIAL, Eisai, Jazz, UCB Pharma.
Ethical Approval: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
